{
    "ticker": "EVOK",
    "name": "Evoke Pharma, Inc.",
    "description": "Evoke Pharma, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for gastrointestinal diseases and disorders. Established in 2010 and headquartered in San Diego, California, Evoke is dedicated to addressing unmet medical needs in the treatment of GI conditions through innovative drug development. The company's lead product candidate, Gimoti, is a nasal spray formulation of metoclopramide designed to treat acute and recurrent diabetic gastroparesis in women. This product aims to provide a non-invasive option for patients who experience significant symptoms that impact their quality of life. Evoke's commitment to research and development is underscored by its focus on creating therapies that can improve patient outcomes and adhere to rigorous regulatory standards. In addition to Gimoti, Evoke is exploring other potential indications and formulations to expand its therapeutic pipeline. With a team of experienced professionals in drug development, regulatory affairs, and commercialization, Evoke is poised to make a significant impact in the field of gastroenterology. The company aims to leverage its expertise to bring innovative solutions to market, ultimately enhancing the lives of patients suffering from gastrointestinal disorders.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2010",
    "website": "https://www.evokepharma.com",
    "ceo": "David G. O'Connor",
    "social_media": {
        "twitter": "https://twitter.com/EvokePharma",
        "linkedin": "https://www.linkedin.com/company/evoke-pharma/"
    },
    "investor_relations": "https://www.evokepharma.com/investors/",
    "key_executives": [
        {
            "name": "David G. O'Connor",
            "position": "CEO"
        },
        {
            "name": "Diana E. H. W. L. Wong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Gimoti"
            ]
        }
    ],
    "seo": {
        "meta_title": "Evoke Pharma, Inc. | Innovative GI Therapeutics",
        "meta_description": "Evoke Pharma, Inc. specializes in developing innovative therapies for gastrointestinal diseases. Learn more about our lead product, Gimoti, and our commitment to patient care.",
        "keywords": [
            "Evoke Pharma",
            "Gimoti",
            "Gastrointestinal Disorders",
            "Biopharmaceuticals",
            "Diabetic Gastroparesis"
        ]
    },
    "faq": [
        {
            "question": "What is Evoke Pharma known for?",
            "answer": "Evoke Pharma is known for developing innovative therapies for gastrointestinal diseases, particularly its product Gimoti for diabetic gastroparesis."
        },
        {
            "question": "Who is the CEO of Evoke Pharma?",
            "answer": "David G. O'Connor is the CEO of Evoke Pharma, Inc."
        },
        {
            "question": "Where is Evoke Pharma headquartered?",
            "answer": "Evoke Pharma is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Gimoti?",
            "answer": "Gimoti is a nasal spray formulation of metoclopramide designed to treat diabetic gastroparesis in women."
        },
        {
            "question": "When was Evoke Pharma founded?",
            "answer": "Evoke Pharma was founded in 2010."
        }
    ],
    "competitors": [
        "NVS",
        "AMGN",
        "ABBV"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "BMY"
    ]
}